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JANUARY 1988
ED IT ORIAL
In the September issue of this newsletter, we printed the following :
"Volunteers are needed for a special Aids vaccine program. You
must have a negative HIV antibodies test reading to qualify .
The program will be held in Bethesda, Maryland with travel ex penses paid. Please call 301-496-7196 for further information . "
Well, before the newsletter even hit the mails, I had called that
number , and was on my way to being a volunteer for the program. I knew
immediately that I had to do this, or at least try. I finally made an
appointment for October 21st for the initial examination. The program
is conducted at The National Institutes of Health in Bethesda, Maryland .
It is technically called "A toxicity/immunogenicity study of a recombinant HIV-envelope protein (gpl60)." This manufactured protein is
identical to the outer coating of the Aids virus . However , i t contains
no live or killed virus, so you will not get Aids.
I was no t ified in early December that I passed my initial exam with
fl y ing colors, so to speak . I returned to Bethesda on December 29t h
and 30th for a complete physical exam plus more blood work, and an
extensive question and answer period. After indicating my desire to
continue on with the program, I was given the vaccine!!!!! I was g : ·- ~n
20ug (units) of gpl60 by injection in the upper arm muscle. I wi ll ~ 2turn to Bethesda once a week for the next four weeks for blood work and
observation. On the fourth week, I will be given a booster shot of 20ug
units more of gpl60. I will then return to Bethesda once a month for
one year. I will periodically give a progress report in this newsletter .
In the meantime, they are still in need of more volunteers for this
program. If you are interested in paricipating in this fantastic opportunity, please call Margaret Megill, R.N. or Victoria Davey, R . N. at
301-496-7196. I would also be happy to relate any information I can to
interested parties - call me (David Ketchum) at 934-4997 - leave a
message, and I will return all calls .
I have nothing but praise for the staff at The National Institutes of
Health. Their dedication , concern, and caring is quite obvious. It is an
uplifting experience that I feel very positive about. It may not be a
cure, but it is certainly a step in the right directjon. We must have
HOPE. Please volunteer NOW .
HUGGING
(THE MIRACLE DRUG)
* IT HELPS THE BODY'S IMMUNE SYSTEM *IT KEEPS YOU HEALTHIER *IT CURES
DEPRESSION *IT REDUCES STRESS
*IT INDUCES SLEEP *IT'S INVIGORATING
*IT'S REJUVENATING *IT HAS NO UNPLEASANT SIDE EFFECTS .. .. .. .

I

PWA COALITION

I am appealing to every PWA, persons with ARC and HIV positive to please
step forward and assist me in forming a PWA coalition in Maine.
I have been a board member of the Maine Health Foundation, worked on joint
ventures with the AIDS Project and listened to a great deal of dialogue of what
is best and can be done for PWAs, persons with ARC and HIV positive. I have been
to Washington and other political activities and also listened. Although very
well intentioned by a body of wonderfully concerned individuals with alot of
love and compassion, who knows better of the needs of this population than the
"silent population" itself? I feel we can better voice our needs, concerns,
and offer a support system that is unsurpassed by any other present group. I
feel we are a group who needs to empower ourselves to help ourselves in various
aspects.
I am not asking anyone to break their anonymity, become politically
active or join any present program. I'm asking for people to get together to
dialogue needs, concerns and how they can best be met.
Needs may vary and
be as simple as to get together with other people with a COITJllOn disease who
understand and dialogue in an informal setting. I have seen this work in other
cormrunities and work well. We have brothers and sisters not getting the
assistance they desperately need for various reasons, let's give them or us
that "safe" place to come together. A place that is not connected to any
program but is an entity unto itself, to help individuals they understand due
to being part of that population. A place to have a united and consistent
voice.
A new year is approaching, let's get together, discuss our needs and concerns in the upcoming year and get to know one another. Society at large wishes
to keep us silent and in our "closets", let's not feed into this and do it ourselves.
.I

On a personal note, I wish to meet others in my situation to come together

and•think there are others out there who feel the same.
Please contact me, Bert, at 775-1259, or Zane or Vincent if you have
any questions, camients and/or interest.
We need your help.
Anonymity assured.
*EDITOR'S NOTE: Persons interested in the formation of a PWA Coalition
in Maine, can also contact David Ketchun at 934- 4997. Bert will be in
New York during the b~;inning of January, therefore, I will pass on
all pertinent information to him when he returns .

From The Office on AIDS
The Community AIDS Education Project
Over
education
response,
education
beginning
religious
schools,
etc.

the past year, interest in AIDS and the need for local AIDS
and information programs have dramatically increased.
In
many local com~unities throughout Maine have developed AIDS
and support services. Many of these conrnunity-based groups are
to feel the overwhelming pressure of providing AIDS education to
groups, civic organizations, local businesses, professionals,
townspeople, social services agencies, health care institutions,

Some groups have discovered that, even in small communities, it's very
difficult to provide AIDS education with limited financial and human
resources. For groups that are staffed by volunteers, there are problems
finding the time and energy to accomplish basic tasks.
The expenses
associated with obtaining and distributing brochures; publicizing meetings
and conferences; and phone, postage, and travel are also limiting the
activities of these groups.
In order to begin addressing these concerns, the state legislature has
appropriated funds to help promote AIDS education efforts at the conrnunity
level. The Office on AIDS will be spearheading this project and is actively
seeking comments from a 11 communitj-based organizations who are offering
AIDS education. Our initial plans include locating your groups and
identifying the areas in Maine where AIDS education is not being addressed,
sponsoring a statewide "get-acquainted" meeting of representatives of your
groups, and conducting a needs assessment to establish how to best apply our
limited funds to this seemingly limitless project. For more information, or
to express your interest in th is project, please contact Peaches Bass,
Office on AIDS, State House Station 11, Augusta, 04333, 289-3747.

AIDS Conference
Documentary

:'\1.-\1~1

Through the help of a $6400 grant from Blue
HUi\1/\N 1Tl E~
'· () l I','· l l
Cross/Blue Shield of Maine, the MHC will be able
ro make a one hour video documentary of its confer·
ence, "AIDS: Plague, Panic and the Test of Human
P.O . BOX 72.02.
Values," which took place this May at the Augusta 371 CUMBERLAND AVENUE
Civic Center. Held before an audience of over 500
PORTLAND , MAINE 04u2.
concerned citizens, the aim of the conference was to
TELEPHONE: (2.07) 773-5051
examine our responses to AIDS in light of the history of other epidemic diseases and the patterns of
LET'S HUG
social, sexual, and cultural conflict that they
produced.
Keynoted by Susan Sontag, the day featured pre·
THERE'S A HUG TO SAY
sentations by medievalist David Herlihy of Brown,
I LOVE YOU
social historian of medicine Allan Brandt of Har·
AND A HUG TO SAY GOODBYE
vard, and theologian Tom Driver of the Union
Theological Seminary; Maine scholars from BowTHERE'S A HUG TO SAY
doin and the University of Maine conducted
HOW ARE YOU
workshops on philosophical, literary, and artistic
AND A HUG TO SAY, WE TRIED
representations of disease in Europe and America .
THERE'S A HUG TO BOND
The dav ended with a series of hard quesnons for
A FRIENDSHIP
. those c~rrently shaping public policy about AIDS in
AND A HUG WHEN THE DAY
Maine. Using excerpts from all of these talks, the
IS THROUGH
Council hopes to capture in this video the dominant
BUT THE HUG I LOVE
sense of the conference: that human reason and
IN ALL THE WORLD IS
discourse can generate hope even in the face of hor·
THE HUG I GET FROM
rifying and real threats to life. The video will be
YOU!
available from the Council.
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The following article is part two in a series of related subjects concerning various drugs used for the treatment of AIDS . It is reprinted wi th
permission from the PWA Coalition of New York City .
ACYCLOVIR
by R. C. Morse
Acyclovir, or ACV, is an antiviral that was initially developed for treatment of herpes
simplex. It is manufactured under the brand name Zovirax by Burroughs Wellcome. Its antiviral action became of interest to AIDS researchers at the National Cancer Institute (NCI)
in Bethesda, Maryland, where it was postulated from cell culture studies that ACV might
work synergisticly with AZT.
An NCI phase one trial began in December 1986 and ended in July 1987 (results are expected to be published this fall in a medical journal) . Eight individuals with symptoms
ranging from ARC to AIDS (KS/PCP) were treated with both AZT and ACV. AZT was administered
at slightly lower dosages than the regimen calls for to lessen its side effects and toxicity .
By administering the two antivirals simultaneously, NCI researchers are attempting to derive
empirical evidence that AZT works better in blocking HIV in tandem with ACV.
Other similar trials are being conducted under the auspices of the National Institute
of Allergy & Infectious Diseases (NIAID), also in Bethesda. Of all government agencies,
NIAID seems to be taking the most aggressive approach to AIDS research . NIAID has established or is establishing Clinical Studies Groups, National Drug Discovery Groups, National
Cooperat i ve Vaccine Development Groups, Vaccine Evaluation Units, AIDS Treatment & Evaluation
Units (ATEUs), as well as a national computerized genetic database for use by medical
professionals.
Some 19 ATEUs were established in 1986 in 11 states, affiliated with some 35 leading
medical and university research centers. As of July 31st, there were 20 active studies
with 1,072 individuals participating at 16 of the centers. Also by the end of July, in
addition to ACV , ATEUs were also evaluating six other AIDS-related drugs. ( NIAID is also
planning a trial for ribavirin, as well as a phase one study for AL-721.)
One of the ATEUs is specifically testing a protocol including both AZT and ACV . This
placebo controlled trial is evaluating the pharmacokinetics and pharmacodynamics of AZT and
ACV when administered concomitantly. Individuals are divided into six distinct groups :
a ) gets a small dose of AZT and no ACV, while b ) gets the same small dose of AZT, but with
800 mg. of ACV; c) do the same with larger doses of AZT ; and e ) and f) the same with regimen levels of AZT. As of the end of July , nine individuals were enrolled in what is expected to be a 12-week study. Once toxicity levels are established, the trial will attempt
to determine if achievable concentration of AZT and ACV have a synergistic activity against
HIV infection.
AMPLIGEN
Ampligen was developed by HEM Research, Inc . of Rockville, MD. HEM is a privately
held company formed in 1966 to analyze and develop mammalian cell culture and growth media.
It later developed compounds to stimulate or amplify the immune system. HEM was the first
company to commercially produce beta interferon.
Its newest product, Ampligen, is a patented, mismatched, double stranded RNA molecule
that may be a therapeutic antiviral for HIV+/ARC/AIDS. The first in vitro trial (an independent study by HEM) ran in 1986 through early 1987 with 10 individuals at George Washington
University and Hahnemann University. The results proved impressive.
In a nutshell , Ampligen may prove to be more powerful than AZT, with no toxic side effects, and may also help to increase the all-critical T4 cell count. According to the study's
authors, their report published in "The Lancet" on June 6th states: Ampligen seems to have
the dual ability to restore immunological functin and to control HIV replication."
Inside an individual's body, Ampligen acts like an artificial virus. The immune system
recognizes Ampligen not as an artifical agent, however, but as the real thing. This subsequently stimulates the body's own natural interferon production. Interferon, in turn,
stimulates the growth and development of healthy red and white blood cells. Ampligen has
also been demonstrated to inhibit HIV virus replication .
The 10 individuals in the study covered the range of infection from ARC to KS/PCP .
They r eceived 200- 250 mg. of Ampligen intravenously twice a week for the duration. According
to results published in "The Lancet", no side effects or toxicity were observed in any of the
individuals involved . After 2-8 doses, seven subjects reported increased energy levels , improved performance status, and lymph node shrinkage. In individuals that were removed from
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treatment after more than a dozen doses, symptoms did not appear again for 2-3 weeks, but
then fatigue and other symptoms began reappearing. When treatment was resumed, the symptoms
again abated.
As an antiviral, Ampligen showed a significant effect in reduction of HIV expression in
9 of the 10 individuals involved in the study, with greatest changes occurring in individuals
with ARC. Acting as a well-tolerated antiviral, Ampligen also seems to have potential as an
immune system modulator. In those individuals with ARC, T4/T8 white cell ratios improved in
as soon as 2-4 weeks of treatment. In those individuals with full-blown AIDS, a 2-5 fold increase in T4 cells occurred at 4 weeks. In total, T4 cell counts rose in 8 of the 10 individuals enrolled in the study.
The authors of the report suggest that Ampligen may have two theoretical advantages
over AZT : no side effects or toxicity. The authors also suggest that Ampligen may be most
efficacious in the early stages of HIV infection, rather than at the state of full-blown
AIDS. They also believe it may work synergisticly with AZT, so that a combination of the
two (with lower, less toxic doses of AZT) may act better on those individuals with fully developed AIDS. Ampligen is also believed to have the ability to cross the blood-brain barrier
treatment AIDS-related neurological disorders.
The potential seen from this preliminary study was enough for Delaware-based DuPont to
acquire a minority equity position in HEM, an action that was announced on May 28th. With
DuPont's manufacturing and clinical capabilities, as well as its previous experience in development and marketing AIDS diagnostics, Ampligen is now being tested further. A clinical
trial with some 200 individuals participating began this summer in New York, Philadelphia,
and Washington, D.C. This is a double-blind, placebo-controlled study. At this time, there
are no plans to test Ampligen concomitantly with AZT. Results from this phase two trial are
expected to be released by the end of the year once the data have been collected and analyzed.

AN ALBUM BY

ARNE HANSON

-----a

FEATURING
DEVONSQUARE/MARY HANSON AND A COLLECTION OF MAINE'S FINEST MUSICIANS.

WHEN YOU BUY THIS ALBUM.
------PARTIAL PROCEEDS WILL GO
TO THE AIDS PROJECT WITH ITS AZT SUPPORT
PROGRAM AND SUPPORT SERVICES FOR AIDS
PATIENTS AND THEIR FAMILIES.
ALBUM OR CASSETIE TAPE $8 .98

SEND $8.98 PLUS $1.00 SHIPPING
& HANDLING TO :
THE AIDS PROJECT
"RECORD"
48 DEERING ST.
PORTLAND, ME 04101
FOR FURTHER INFORMATION CALL:
(207) 774-~$'7'7

TRIBUTE TO MICHAEL HANSEN
by Tom Cunningham
Michael Hansen died of AIDS on June 27th at age 31.
Michael was a gifted actor, singer/songwriter, and
teacher, who touched all that he met with warm,
unconditional love. He will be remembered by this
love, his humor, his beauty, and his music. He
will be missed by many forever. The following is
a song of love and great hope he wrote and recorded after his diagnosis:
WE'VE GOT TODAY
We got problems, kid
and the rent is barely paid
They turned the phone off
my bal is never made
They're talking deadlines
they're talking hard times ahead
They're printing headlines
that keep the fatalistics fed
They're cutting lifelines instead
But we -'ve got today
no matter what they say, we've got today
and that's time enough to say
how much you mean to me
Pastures are green to me
when I know you care
There's so many would've run
there's so many would condemn
but here you are
just loving me again
We're sharing secrets
we're laughing harder than we did
We're staying up late
acting like we're kids
We're trading teardrops we've hid • •.

"I'm sorry , s,r, but tlHS survey does nol allo w
for lhal opinion ."

So it's love over everything
with laughter as my friend
My tears are crystals
that help me start again
It's a teddy bear to take the place
of dragons that I slay
It's a light that shines so simply
even if it's night or day

--

We've got today
No matter what they say, we've got today
and that's time enough to say
how much you mean to me
pastures are green to me
when I know you care
We've got today .••
(Copywright 1986 by Michael Hansen)

Reprinted with permission
from the PWA Coalition
of New York City.
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D!HECTLY SPEAKING
by
Gary L. Anderson

Safety Tips for
Vacation. .Trips
.
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It was Just about this time
three years ago that I first became
active in the AIDS arena. That may
not seem like a very long time ago,
but then there was no such thing as
the AIDS Project . It has taken alot
of work by alot of dedicated people
to get us where we are today.
But the work that needs doing
has Just begun . The epidemic of HIV
disease in this state is sti 11
nascent and it will be years before
its full impact is felt.
Compared
to the future, these past few years
have been the easy ones.
The AIDS ProJect has made many
contributions in the fight against
the spreao of HIV disease in Maine
and in providing support services to
t~ose Maine people who have HIV
disease. The AIDS Project has grown
ano changed along the way.
A
grassroots organization meeting in
churches and a bookstore has become
a corporate entity, an agency . And
it will continue to grow and change
as the epidemic spreads .
1988 wi 11 be a hard year for
the people of Maine. More and more
people in our lives will be touched
by HIV disease.
The role of the
AIDS Project wi 11 become ever more
crucial.
As the AIDS Project struggles
to expand and improve the caliber of
its services, some important changes
wl 11 take place. We wi 11 count on
your support during these periods of
transition.
It has been your
support and encouragement over the
past three years that has kept us
going. But, your support will never
oe neecea more than it wl 11 be in
the year we ' ve Just begun.
So bear
with us . Or, better yet, help bear
us along or. our way to becoml ng a
oetter agency .
The real work is still ahead.

AIDS Proiect Hosts
Hol Jday DJnner

On Sunday, Dec. 20th, the AIDS
Project Board of Directors hosted a
Christmas dinner at Boone's ln Port! and.
Twenty-one persons with HIV
disease and their special guests
were ln attendance.
A surprise
visit from Santina CSanta was busy
elsewhere> heightened the good will
and good cheer of the evening.
Thanks go to Robert Mi tche I 1 ,
Board President, and Lucy Marbach,
Client Services Coordinator, for
thier hard work in pulling this off
Cand Lucy especially for finding all
the right gifts>. Thanks to Kristen
Kreamer for her jocular ad-libbing
performance as Santina.

SAFER
SEX
CAN BE SENSUOUS!

~
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SOME THOUGHTS ON AIDS ISSUES
By Mike Ossias
I have a few thoughts on AIDS and AZT that might help the newly diagnosed, and figured
it was about time I wrote something for your Newsline. Credentials first: I presented with
PCP in November 1985. I'd been ARC for a year or so, but my friendly (ex) GP basically
fudged, and I was too ignorant and unwilling to look at what was going on to question him
fully. This leads to my first point. It's really important for you to get as much information as possible on not just the major aspects of the disease, but also on all sorts of
smaller annoyances that can crop up. You can do this in a mammoth library session, or by
asking other PWAs, and definitely by asking your doctor to explain things. A lot of doctors
are very casual in their explanations, but it's important to press them.
Have a dialogue with your doctor. The only way you can do this successfully is to become at least passingly familiar with the pertinent medical terms and with the body's workings.
We differ in our capacities to absorb medical information, but we can achieve a certain degree
of medical literacy, especially about AIDS and ARC, and that's vital. I've heard too many
horror stories in the past two years to believe that all the doctors treating AIDS actually
know what they're doing. The more you know, the less you might suffer.
On to AZT. Yeah, another opinion, but based on a lot more experience than most. I participated in the Phase II trials that began in April 1986 and led to release of the drug. In
fact, I was the first person in the New York City trials to get AZT (as opposed to placebo).
That was in April '86, and I'm still on AZT. I can tell you that it created a significant
improvement in the quality of my day-to-day existence with AIDS. No, AZT does not prevent
PCP -- I found that out the hard way. No, AZT has not prevented the emergence of KS in my
body, though it may have slowed it down. And yes, I've been affected by the toxicity, put
on half dose, and been given innumerable transfusions (well, at least 15; I've lost count).
Apparently I had the dubious distinction of being one of the most sensitive in the study to
the bone marrow suppressive qualities of the drug. So much for negatives. The fact is, AZT
is doing a lot of good for a lot of people, and I've personally seen some miraculous results
of going on it.
That's why I get irritated when people criticize AZT for not doing more. It's not a
panacea and no one said, ever, that it was a cure. But to refer to it, as Michael Callen did
recently, as "that poison" is simply irresponsible. Some of us know better, but someone newly
diagnosed is still feeling his or her way, and deserves not to be terrorized.
To those trying to decide whether or not to go on AZT, I'd say, try to find out about
others' actual experience with the drug and weigh the symptoms you hear about against the acknowledged benefits. Transfusions are really not so bad; neither are minor headaches. The
fact is, as Donna Mildvan of Beth Israel said in a response to a question about AZT's toxicity,
"AZT is not as toxic as AIDS". And there's nothing else yet available that addresses the virus
itself successfully. Think about it. You can always go off AZT if you really feel you're
suffering being on it.
A couple of last comments. I agree fully with Michael Callen that no one should have to
give up PCP prophylaxis to participate in a study. I came thrdugh my second bout of PCP easily enough, but I wasn't happy about it. For what it's worth, and without ui:g.ng "unethical"
behavior, let me just say that the blood work done for the AZT study did not detect Bactrim.
But it's a tricky game to play, trying to be on prophylaxis and stay in a study. We shouldn't
have to make such a choice.

~11-~~l\JJj~
SUBSCRIBE NOW TO THE AIDS PROJECT NEWSLETTER
THIS NEWSIETTER RELIES TCYI'ALLY ON SUBSCRIPI'IONS TO EXIST. WE
ARE GRATEFUL TO THOSE WHO HAVE SUBSCRIBED, AND TO THOSE WHO
HAVE NCYI', PIEASE DO so NOW. s10.oo COVERS ONE YEAR (12 ISSUES).
PIEASE MAKE YOUR CHECK OR MONEY ORDER PAY.ABLE TO "THE AIDS
PROJECT". THANK YOU.

---------------------------------------------------------------

*NOTE: The article on page 8 entitled "Some Thoughts On Aids Iss•.1es", was
reprinted with permission from the PWA Coalition of New York City.
CALENDAR
JAN.15-17-Conference On Aids Ministry - Westin Oaks Galleria Hotel - Houston
Texas - Designed by gay/lesbian people specifically for the gay/
lesbian community - Sponsored by Samaritan College and The UFMCC
Board of Elders - Call 1-800-642-4386 for further information.
JAN. 16 - "The Emotions of AIDS" - a one day workshop conducted by
Jacob Watson , M.A. and Kristine Myers, M.A. - University of
Southern Maine Portland - 9am - 4pm - contact Jacob at 761-2522
or Kristine at 775-0366 for further information.
JAN. 23 - The Merrymeeting Aids Support Services group will be conducting a
"Buddy" training session - 9:00 am to 5:00 pm - location to be
announced - call 729-8727 for further information.
MAR.21-22-Interfaith Conference on AIDS and ARC - for detailed information
contact: AIDS/ARC Conferenc~ Proceedings - c/o Shanti Project 525 Howard Street - San Francisco, California 94105.
SPRING
1988

- Aids Prevention Education Conference Follow-Up - Maine Medical
Center - call 871-2131 for further information.

JUL.20-26-The Second International Lesbian and Gay Health Conference and
AIDS Forum - Call For Participation - Boston Park Plaza Hotel an~
Towers - To submit a proposal and for registration information
contact NLGHF/AAPHR Programming Committee - P.O. Box 65472 Washington, D.C. 20035 or contact Michael Weeks at 202-797-3708
or Greg Thomas at 202-994-4285,
ONGOI'.'JG CALENDAR
Every Tuesday from 10:30am to 12noon
Street - Portland - there is a group
givers, and family members, to share
to Aids. The meeting is conducted by
psychotherapist specializing in loss
of the Elizabeth Kubler-Ross Center.

at The Aids Project - 48 Deering
meeting for all PWA's, PWArc, careyour thoughts and feelings relative
Jacob Watson, M. A. Jacob is a
and transition and is a staff member

Every Tuesday evening 7:00pm to 8:30pm at 29 Cushman Street - Portland there is a group meeting for all lovers, caregiv~rs, friends, and family
members only. The meeting will be conducted by Brooke Alexander, an
Episcopal priest and pastoral counselor. Call Brooke at 772-1678 or Lucy
Marbach at The Aids Project 774-6877 for further information.
Support Group for Parents of Adult Gay Children will meet the 2nd Tuesday
of every month. Please call 774-HELP for time and place.
Support group for Parents and Friends of Gays will meet the 4th Tuesday
of every month at the Pilgrim House - 9 Cleaveland St. - Brunswick, Me. Call 729-9843 for further information .
There is now an AIDS support group in the Bangor area meeting every Thursday evening . Anyone interested in the group should call 469-7343 or write
EMAN - P.O.Box 2038 - Bangor, Maine 04401

WHEN YOU SEE SOMEONE WITHOUT A SMILE,
GIVE THEM ONE OF YOURS ........ .

TAP
48 DEERING STREET
PORTLAND, MAINE 04101

IULK RATE
TMIIID Cl.ASS MAIL
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